Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/15/2862734/0/en/Neurona-Therapeutics-Presents-Positive-Clinical-Update-from-NRTX-1001-Cell-Therapy-Trial-in-Adults-with-Drug-resistant-Focal-Epilepsy-at-American-Academy-of-Neurology-AAN-2024-Annu.html
https://www.globenewswire.com//news-release/2024/03/12/2844986/0/en/Neurona-Therapeutics-to-Present-at-Stifel-2024-Virtual-CNS-Days.html
https://www.globenewswire.com//news-release/2024/03/07/2842708/0/en/Neurona-Therapeutics-Announces-Presentation-of-Updated-Clinical-Data-at-the-Upcoming-American-Academy-of-Neurology-AAN-Annual-Meeting-from-Lead-Cell-Therapy-Candidate-NRTX-1001.html
https://www.fiercebiotech.com/biotech/dont-call-it-comeback-neurona-knocks-out-120m-raise-year-after-layoffs
https://endpts.com/neurona-raises-120m-to-take-epilepsy-cell-therapy-to-late-stage-development/
https://www.globenewswire.com//news-release/2024/02/07/2825535/0/en/Neurona-Therapeutics-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Lifesciences-Conference.html
https://www.globenewswire.com//news-release/2023/12/01/2789334/0/en/Neurona-Therapeutics-Presents-New-Clinical-Data-from-First-Cohort-in-Ongoing-Phase-I-II-Open-Label-Trial-of-NRTX-1001-Cell-Therapy-for-Drug-resistant-Mesial-Temporal-Lobe-Epilepsy-.html
https://www.globenewswire.com//news-release/2023/10/19/2763149/0/en/Neurona-Therapeutics-Completes-Clinical-Enrollment-of-First-Cohort-and-Updates-on-Long-lasting-Impact-in-First-Patients-Treated-in-Ongoing-Phase-I-II-Trial-of-NRTX-1001-Cell-Therap.html
https://www.globenewswire.com//news-release/2023/10/10/2757892/0/en/Neurona-Therapeutics-Announces-Participation-in-Upcoming-Investor-Conferences-in-October.html
https://www.globenewswire.com//news-release/2023/10/05/2755586/0/en/Neurona-Therapeutics-Announces-Publication-in-Cell-Stem-Cell-Reporting-the-Development-of-Investigational-Novel-Regenerative-Cell-Therapy-Strategy-for-Drug-resistant-Focal-Epilepsy.html